Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Neurofibromatosis Type 1Sarcoma
Interventions
BIOLOGICAL

filgrastim

Given subcutaneously

DRUG

doxorubicin hydrochloride

Given IV

DRUG

etoposide

Given IV

DRUG

ifosfamide

Given IV

PROCEDURE

conventional surgery

Patients undergo surgery

RADIATION

radiation therapy

Patients undergo radiotherapy

Trial Locations (17)

15213

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

19106

Pennsylvania Oncology Hematology Associates, Philadelphia

28203

Carolinas Hematology-Oncology Associates, Charlotte

35294

UAB Comprehensive Cancer Center, Birmingham

52242

University of Iowa Hospitals and Clinics, Iowa City

55455

University of Minnesota, Minneapolis

60614

Children's Memorial Hospital - Chicago, Chicago

84112

Huntsman Cancer Institute at University of Utah, Salt Lake City

90403

Sarcoma Oncology Center, Santa Monica

98109

Seattle Cancer Care Alliance at Washington University, Seattle

46202-5289

Indiana University, Indianapolis

21231-2410

Johns Hopkins, Baltimore

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

48109-0942

University of Michigan Comprehensive Cancer Center, Ann Arbor

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sarcoma Alliance for Research through Collaboration

OTHER

NCT00304083 - Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors | Biotech Hunter | Biotech Hunter